Grünenthal Fully Acquires Grünenthal Meds, Strengthening Its Market Position Grünenthal has successfully taken full ownership of Grünenthal Meds from Kyowa Kirin, enhancing its reach in established medicine markets across 60+ regions.

Grünenthal Fully Acquires Grünenthal Meds, Strengthening Its Market Position #Germany #Grünenthal #Aachen #Kyowa_Kirin #Grünenthal_Meds

Amgen and Kyowa Kirin Reveal Promising Top-Line Results from Rocatinlimab Phase 3 Study for Atopic Dermatitis The ASCEND study shows the potential of rocatinlimab as a long-term treatment for adults with moderate to severe atopic dermatitis, paving the way for innovative therapies.

Amgen and Kyowa Kirin Reveal Promising Top-Line Results from Rocatinlimab Phase 3 Study for Atopic Dermatitis #USA #Amgen #Thousand_Oaks #Kyowa_Kirin #Rocatinlimab

Kyowa Kirin to Present Important Findings on Rocatinlimab at EADV 2025 Congress Kyowa Kirin is set to present the Phase 3 trial results of Rocatinlimab, a promising therapy for atopic dermatitis, at the EADV congress in Paris.

Kyowa Kirin to Present Important Findings on Rocatinlimab at EADV 2025 Congress #Japan #Tokyo #Atopic_Dermatitis #Kyowa_Kirin #Rocatinlimab

Kyowa Kirin to Present Groundbreaking Findings on Rocatinlimab at EADV 2025 Kyowa Kirin Co., Ltd. is set to unveil results from the Phase 3 ROCKET IGNITE trial of rocatinlimab targeting atopic dermatitis at EADV 2025 in Paris.

Kyowa Kirin to Present Groundbreaking Findings on Rocatinlimab at EADV 2025 #Japan #Tokyo #Kyowa_Kirin #Rocatinlimab #EADV_2025

Renewal of 35-Year Partnership Between La Jolla Institute and Kyowa Kirin for Scientific Advances The La Jolla Institute for Immunology and Kyowa Kirin renew their collaboration for three years, aiming for groundbreaking advancements in immunology and patient therapies.

Renewal of 35-Year Partnership Between La Jolla Institute and Kyowa Kirin for Scientific Advances #United_States #La_Jolla #Kyowa_Kirin #La_Jolla_Institute #Immunology_Research

Amgen and Kyowa Kirin Announce Promising Results for Rocatinlimab in Treating Atopic Dermatitis Amgen and Kyowa Kirin revealed exciting findings from the Phase 3 IGNITE study regarding their treatment for atopic dermatitis, showcasing significant improvements.

Amgen and Kyowa Kirin Announce Promising Results for Rocatinlimab in Treating Atopic Dermatitis #USA #Amgen #Thousand_Oaks #Kyowa_Kirin #Rocatinlimab

Kyowa Kirin to Present Groundbreaking Findings from ROCKET HORIZON at AAD 2025 Kyowa Kirin recently announced the presentation of significant findings from the ROCKET HORIZON trial of rocatinlimab during the AAD 2025 conference.

Kyowa Kirin to Present Groundbreaking Findings from ROCKET HORIZON at AAD 2025 #Japan #Princeton #Kyowa_Kirin #Rocatinlimab #AAD_2025